Teva Pharmaceutical Industries saw the highest growth of 1.63% in patent filings and 0.74% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.63% and grants by 0.74%. GlobalData’s DataBook provides a comprehensive analysis of Teva Pharmaceutical Industries‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Teva Pharmaceutical Industries has been focused on protecting inventions in United States(US) with 21 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 34% filings and 16% grants. The United States(US), European Patent Office(EPO), Japan(JP), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Teva Pharmaceutical Industries is filings its patents. Among the top granted patent authorities, Teva Pharmaceutical Industries has 16% of its grants in United States(US), 16% in European Patent Office(EPO) and 9% in Japan(JP).
AptarGroup and Philip Morris International could be the strongest competitors for Teva Pharmaceutical Industries
In terms of grant share, Teva Pharmaceutical Industries stands first among its competitors followed by AptarGroup and Philip Morris International.
Patents related to rare diseases and healthtech lead Teva Pharmaceutical Industries's portfolio
Teva Pharmaceutical Industries has the highest number of patents in rare diseases followed by, healthtech and remote patient monitoring. For rare diseases, nearly 33% of patents were filed and 11% of patents were granted in Q2 2024.
Hyperkinesia related patents lead Teva Pharmaceutical Industries portfolio followed by other remote patient monitoring, and asthma
Teva Pharmaceutical Industries has highest number of patents in hyperkinesia followed by other remote patient monitoring, asthma, anesthesia and respiratory devices, and chronic obstructive pulmonary disease (copd). For hyperkinesia, nearly 6% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Teva Pharmaceutical Industries's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
